Overview

• US laboratory furniture maker's fiscal Q4 sales fell 7.5% yr/yr

• Adjusted EPS for fiscal Q4 declined from prior year

• Company cites lower manufacturing volumes and shipment timing as reasons for Q4 declines

Outlook

• Company says it is positioned to continue executing its growth strategy in fiscal 2027

• Company expects improved performance as life sciences market conditions recover

• Company remains focused on disciplined capital allocation and operational execution

Result Drivers

• LAB PRODUCTS GROUP VOLUMES - Lower manufacturing volumes in the laboratory construction business, due to continued volatility in project delivery timelines, weighed on Q4 results

• INTERNATIONAL SHIPMENT TIMING - Lower billings, principally related to shipment timing for projects in the Middle East, reduced International segment profitability

• CORPORATE INVESTMENTS - Continued strategic investments in people, processes, and technology increased corporate segment losses

Company press release: ID:nPncLJBka

Key Details

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.